MT Newswires
Biogen, Eisai Report Long-Term Data Showing Patients Choose to Stay on Lecanemab Treatment
➖
AI Sentiment
Neutral
5/10
Biogen Inc. News
Latest updates and market news for BIIB
6 news
Mar 16 - Mar 22, 2026
Page 1
GlobeNewswire
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026
📈
AI Sentiment
Highly Positive
9/10
GlobeNewswire
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting
📈
AI Sentiment
Highly Positive
9/10
MarketBeat
Biogen Conference: Tau ASO CELIA Updates, Pre-Symptomatic Leqembi, SMA Phase 3 Plans
📈
AI Sentiment
Highly Positive
8/10
MT Newswires
HSBC Adjusts Price Target on Biogen to $150 From $143, Maintains Reduce Rating
📈
AI Sentiment
Highly Positive
8/10
Simply Wall St.
Biogen (BIIB) Valuation Check As New SMA Data And Phase 3 Plans Draw Fresh Growth Focus
📊
AI Sentiment
Positive
7/10
Share this news page